SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Cited by (785)

Items 401–500 of 785

1. Cannabinoid control of gingival immune activation in chronically SIV-infected rhesus macaques involves modulation of the indoleamine-2,3-dioxygenase-1 pathway and salivary microbiome
   Marina McDew-White, E. Lee, X. Alvarez, K. Sestak, B. Ling, S. Byrareddy, C. Okeoma, Mahesh Mohan · 2021 · EBioMedicine
2. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2
   Lisa H. Tostanoski, Lisa E. Gralinski, David R. Martinez, A. Schaefer, S. Mahrokhian, Zhen-Feng Li, Felix Nampanya, Hua-Hua Wan, Jing-You Yu, Aiquan Chang et al. · 2021 · bioRxiv
3. Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries
   M. Siedner, Christopher Alba, K. Fitzmaurice, R. Gilbert, J. A. Scott, Fatma M. Shebl, Andrea L. Ciaranello, K. P. Reddy, K. Freedberg · 2021 · medRxiv
4. Severe SARS-CoV-2 infection in a cat with hypertrophic cardiomyopathy
   F. Carvallo, Mathias Martins, Lok Raj Joshi, L. Caserta, Patrick K. Mitchell, T. Cecere, Sandy Hancock, Erin L. Goodrich, Julia M. Murphy, D. Diel · 2021
5. Roborovski hamster (Phodopus roborovskii) strain SH101 as a systemic infection model of SARS-CoV-2
   Chong-Kai Zhai, Ming-Da Wang, Hea-Jong Chung, Mehedi Hassan, Seungkoo Lee, Hyeon-Jin Kim, Seong-Tshool Hong · 2021 · Virulence
6. Coronavirus vaccine-associated lung immunopathology-what is the significance?
   M. Bottazzi, Ulrich Strych, P. Hotez, D. Corry · 2020 · Microbes and infection
7. Small Particle Aerosol Exposure of African Green Monkeys to MERS-CoV as a Model for Highly Pathogenic Coronavirus Infection
   Allison L. Totura, Virginia Livingston, Ondraya M. Frick, David Dyer, D. Nichols, Aysegul Nalca · 2020 · Emerging Infectious Diseases
8. A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus
   Zhenzhen Wang, Zhenhua Li, Weiwei Shi, Dashuai Zhu, Shiqi Hu, Phuong‐Uyen Dinh, Ke Cheng · 2023 · Science Advances
9. Needle‐free injection system delivery of ZyCoV‐D DNA vaccine demonstrated improved immunogenicity and protective efficacy in rhesus macaques against SARS‐CoV‐2
   P. Yadav, Sanjay Kumar, K. Agarwal, M. Jain, Dilip R Patil, Kapil Maithal, B. Mathapati, S. Giri, S. Mohandas, A. Shete et al. · 2023 · Journal of Medical Virology
10. Modelling the response to vaccine in non-human primates to define SARS-CoV-2 mechanistic correlates of protection
    Marie Alexandre, R. Marlin, M. Prague, Séverin Coléon, Nidhal Kahlaoui, Sylvain Cardinaud, Thibaut Naninck, B. Delache, M. Surenaud, Mathilde Galhaut et al. · 2022 · eLife
11. Mouse models in COVID-19 research: analyzing the adaptive immune response
    S. Clever, A. Volz · 2022 · Medical Microbiology and Immmunology
12. An immunoPET probe to SARS-CoV-2 reveals early infection of the male genital tract in rhesus macaques
    Patrick Madden, Y. Thomas, R. Blair, S. Samer, Mark Doyle, C. Midkiff, L. Doyle-Meyers, Mark E. Becker, M. S. Arif, Michael D. McRaven et al. · 2022 · Research Square
13. SARS-CoV-2 Infection of Rhesus Macaques Treated Early with Human COVID-19 Convalescent Plasma
    J. Deere, Timothy D. Carroll, Joseph C. Dutra, L. Fritts, R. Sammak, J. Yee, K. Olstad, J. Reader, A. Kistler, J. Kamm et al. · 2021 · Microbiology spectrum
14. Monoclonal antibodies protect aged rhesus macaques from SARS-CoV-2-induced immune activation and neuroinflammation
    A. Verma, Chase Hawes, Y. S. Lakshmanappa, Jamin W. Roh, B. Schmidt, Joseph C. Dutra, William Louie, Hong-Wei Liu, Zhong-Min Ma, Jennifer K. Watanabe et al. · 2021 · Cell Reports
15. SARS-CoV-2 in Pregnant Women: Consequences of Vertical Transmission
    Ishaan Chaubey, R. Vignesh, Hemalatha Babu, Isabelle Wagoner, Sakthivel Govindaraj, V. Velu · 2021 · Frontiers in Cellular and Infection Microbiology
16. Longitudinal analysis of SARS-CoV-2 seroprevalence using multiple serology platforms
    J. Carreño, D. Mendu, V. Simon, M. Shariff, Gagandeep Singh, V. Menon, F. Krammer · 2021 · medRxiv
17. SARS-CoV-2 virus: Vaccines in development
    Qing-Rui Huang, Jing-Hua Yan · 2021 · Fundamental Research
18. Strategy, coordinated implementation, and sustainable financing needed for COVID-19 innovations
    V. Dzau, C. Balatbat · 2020 · The Lancet
19. Return to School for Pediatric Solid Organ Transplant Recipients in the United States During the Coronavirus Disease 2019 Pandemic: Expert Opinion on Key Considerations and Best Practices
    Kevin J. Downes, L. Danziger-Isakov, Melissa K. Cousino, Michael R. Green, M. Michaels, W. Muller, R. Orscheln, Tanvi S. Sharma, Victoria A Statler, Rachel L. Wattier et al. · 2020 · Journal of the Pediatric Infectious Diseases Society
20. Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
    Mingtao Liu, Hui Gan, Zhi-Man Liang, Li Liu, Qi-Wen Liu, Yiyin Mai, Hui-Huang Chen, Baoying Lei, Shangwei Yu, Hui-Hui Chen et al. · 2023 · Frontiers in Microbiology
21. Antibody development and disease severity of COVID-19 in non-immunised patients with rheumatic immune-mediated inflammatory diseases: data from a prospective cohort study
    L. Boekel, F. Hooijberg, E. Vogelzang, Y. Besten, M. Leeuw, S. Atiqi, Ronald F. van Vollenhoven, C. Wijbrandts, M. Gerritsen, C. Krieckaert et al. · 2022 · RMD Open
22. Association of follicular helper T and follicular regulatory T cells with severity and hyperglycemia in hospitalized COVID-19 patients
    Asmaa M. Zahran, Mona H. Abdel-Rahim, K. Nasif, Safinaz Hussein, R. Hafez, A. Ahmad, Khaled Saad, Amira A. Elhoufey, Hosni A. M. Hussein, Ali A. Thabet et al. · 2022 · Virulence
23. Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses
    E. Marklund, S. Leach, Kristina Nyström, A. Lundgren, J. Liljeqvist, S. Nilsson, A. Yilmaz, L. Andersson, M. Bemark, M. Gisslén · 2021 · Frontiers in Immunology
24. Pandemic Stress and Its Correlates among Pregnant Women during the Second Wave of COVID-19 in Poland
    M. Ilska, A. Kołodziej-Zaleska, Anna Brandt-Salmeri, H. Preis, M. Lobel · 2021 · International Journal of Environmental Research and Public Health
25. Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing
    Ping-Sen Zhao, J. Zou, Fan Zhou, Yanyan Zhu, Q. Song, Dong-Dong Yu, Xiang-Pan Li · 2021 · International Immunopharmacology
26. Reverse zoonosis of coronavirus disease-19: Present status and the control by one health approach
    R. Pramod, Asha V Nair, Padmakar Tambare, Kanchana Chauhan, T. V. Kumar, R. Rajan, B. M. Mani, Muhasin Asaf, A. Pandey · 2021 · Veterinary World
27. Severe SARS-CoV-2 Infection in a Cat with Hypertrophic Cardiomyopathy
    F. Carvallo, Mathias Martins, Lok Raj Joshi, L. Caserta, Patrick K. Mitchell, T. Cecere, Sandy Hancock, Erin L. Goodrich, Julia M. Murphy, D. Diel · 2021 · Viruses
28. A SARS-CoV-2 Label-Free Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients
    Yi-Qi R. Luo, C. Yun, I. Chakraborty, A. Wu, K. Lynch · 2021 · Journal of Clinical Microbiology
29. Assessment of immunogenicity and protective efficacy of ZyCoV-D DNA vaccine candidates in Rhesus macaques against SARS-CoV-2 infection
    P. Yadav, Sanjay Kumar, K. Agarwal, M. Jain, Dilip R Patil, Kapil Maithal, B. Mathapati, S. Giri, S. Mohandas, A. Shete et al. · 2021 · bioRxiv
30. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization
    Maggie Gu, J. Torres, Yi-Jia Li, Alex Van Ry, Jack Greenhouse, Shannon E. Wallace, Chi-I Chiang, Laurent Pessaint, A. Jackson, Maciel Porto et al. · 2021 · Emerging Microbes and Infections
31. Two-tiered SARS-CoV-2 seroconversion screening in the Netherlands and stability of nucleocapsid, spike protein domain 1 and neutralizing antibodies
    Anja Garritsen, Anja Scholzen, Daan W. A. van den Nieuwenhof, Anke P. F. Smits, E. Suzan Datema, Luc S. van Galen, Milou Kouwijzer · 2021 · Scandinavian Journal of Infectious Diseases
32. COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID
    C. Fiorella, Galleguillos Lorna · 2020 · Multiple Sclerosis and Related Disorders
33. SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
    Hong-Yu Liang, Yu-Yan Wu, V. Yau, Huan-Xin Yin, S. Lowe, Rachel E. T. Bentley, M. Ahmed, Wenjing Zhao, Chen-Yu Sun · 2022 · Vaccines
34. Carbohydrates Metabolic Signatures in Immune Cells: Response to Infection
    K. Awad, A. Maghraby, D. Abd-Elshafy, M. Bahgat · 2022 · Frontiers in Immunology
35. Initiation of the Primate Genome Project
    Dong-Dong Wu, Xiao-Li Qi, Li Yu, Ming Li, Zhi-Jin Liu, A. Yoder, C. Roos, T. Hayakawa, Jeffrey Rogers, T. Marqués-Bonet et al. · 2022 · Zoological Research
36. Serological Markers of SARS-CoV-2 Reinfection
    S. Siddiqui, K. Bowman, A. Zhu, S. Fischinger, Samuel Beger, Jenny S. Maron, Y. Bartsch, C. Atyeo, M. Gorman, Ahmad H. Yanis et al. · 2022 · mBio
37. Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2
    Ian F. Miller, Charlotte Jessica E. Metcalf · 2022 · Royal Society Open Science
38. COVID-19 Animal Models and Vaccines: Current Landscape and Future Prospects
    Shen Wang, Ling Li, Fei-Hu Yan, Yu-Wei Gao, Song-Tao Yang, X. Xia · 2021 · Vaccines
39. Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies
    Magdalena M. Zak, Aryeh Stock, D. Stadlbauer, Wei Zhang, K. Cummings, William Marsiglia, Arsen Zargarov, Fatima Amanat, M. Tamayo, C. Cordon-Cardo et al. · 2021 · Heliyon
40. Persistence of humoral response upon SARS‐CoV‐2 infection
    Andrea Knies, Dennis Ladage, Ralf J. Braun, Janine Kimpel, Miriam Schneider · 2021 · Reviews in Medical Virology
41. Combination of a Sindbis-SARS-CoV-2 Spike Vaccine and αOX40 Antibody Elicits Protective Immunity Against SARS-CoV-2 Induced Disease and Potentiates Long-Term SARS-CoV-2-Specific Humoral and T-Cell Immunity
    A. Scaglione, S. Opp, A. Hurtado, C. Pampeno, Ziyan Lin, Maria G. Noval, Sara A. Thannickal, Kenneth A. Stapleford, D. Meruelo · 2021 · bioRxiv
42. Comparative analyses of ACE2 and TMPRSS2 gene: Implications for the risk to which vertebrate animals are susceptible to SARS‐CoV‐2
    Chen Huang, Yu Jiang, Jie Yan · 2021 · Journal of Medical Virology
43. The COVID‐19 pandemic: key considerations for the epidemic and its control
    Søren ørskOV, B. F. Nielsen, Sofie Føns, K. Sneppen, L. Simonsen · 2021 · Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS)
44. Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection
    L. Muir, Aneesa Jaffer, C. Rees-Spear, Vignesh Gopalan, F. Chang, R. Fernando, Gintare Vaitkute, C. Roustan, Annachiara Rosa, Christopher Earl et al. · 2021 · Kidney International Reports
45. The role of pseudotype neutralization assays in understanding SARS CoV-2
    D. Cantoni, M. Mayora-Neto, N. Temperton · 2021 · Oxford Open Immunology
46. Key residues influencing binding affinities of 2019-nCoV with ACE2 in different species
    S. Fang, Ruoqian Zheng, Chuqi Lei, Jian-Xin Wang, Rui-Qing Zheng, Min Li · 2020 · Briefings Bioinform.
47. Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19
    Natalie M. Kirk, Yu-Ying Liang, H. Ly · 2024 · Virulence
48. Immune response induced by novel coronavirus infection
    Ying Sun, Yawen Zou, Haiyu Wang, Guangying Cui, Zujiang Yu, Zhigang Ren · 2022 · Frontiers in Cellular and Infection Microbiology
49. Characteristics of animal models for COVID‐19
    Fei-Fei Qi, Chuan Qin · 2022 · Animal Models and Experimental Medicine
50. Characterization of Immune Response Diversity in Rodents Vaccinated with a Vesicular Stomatitis Virus Vectored COVID-19 Vaccine
    Shen Wang, Cheng Zhang, B. Liang, Wei-Qi Wang, N. Feng, Yong-Kun Zhao, Tie-Cheng Wang, Zhen-Dong Guo, Fei-Hu Yan, Song-Tao Yang et al. · 2022 · Viruses
51. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection
    Amy J. Schuh, Panayampalli Subbian Satheshkumar, Stephanie Dietz, Lara Bull–Otterson, Myrna D. Charles, Chris Edens, Jefferson M. Jones, Kristina L. Bajema, Kristie E.N. Clarke, L. Clifford McDonald et al. · 2022 · Microbiology Spectrum
52. Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
    Nawamin Sa-nguanmoo, K. Namdee, M. Khongkow, Uracha Ruktanonchai, Yong-Xiang Zhao, Xing-Jie Liang · 2021 · Nano Reseach
53. Recovery from Acute SARS-CoV-2 Infection and Development of Anamnestic Immune Responses in T Cell-Depleted Rhesus Macaques
    K. Hasenkrug, F. Feldmann, Lara M. Myers, Mario L. Santiago, K. Guo, Bradley S. Barrett, Kaylee L. Mickens, A. Carmody, A. Okumura, Deepashri Rao et al. · 2021 · mBio
54. Comparative analysis of antibodies to SARS-CoV-2 between asymptomatic and convalescent patients
    Connor J. Dwyer, Colleen A. Cloud, Cindy Wang, P. Heidt, Paramita Chakraborty, Tara Duke, Shannon McGue, Braxton Jeffcoat, J. Dunne, L. Johnson et al. · 2021 · iScience
55. Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies
    M. Bubonja-Šonje, Lara Batičić, M. Abram, Đurđica Cekinović Grbeša · 2021 · Journal of Virological Methods
56. Factors Influencing Viral Clearance in Mild COVID-19 and Clinical Characteristics of Asymptomatic Patients
    Hong-Mei Shu, Shibin He, Yong Sun, Chang-Qing Lin, Yu-fang Lu, Jing Liu, Ting Wu, Li Li, Guo-Zheng Ding, Wei Shi et al. · 2021 · BioMed Research International
57. Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mouse and non-human primates
    Nerea Zabaleta, Wenlong Dai, Urja Bhatt, Jessica A Chichester, Julio Sanmiguel, Reynette Estelien, Kristofer T Michalson, Cheikh Diop, Dawid Maciorowski, Wenbin Qi et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
58. Evolution of immunity to SARS-CoV-2
    A. Wheatley, J. Juno, Jing J. Wang, K. Selva, A. Reynaldi, Hyon-Xhi Tan, W. Lee, Kathleen M. Wragg, Hannah G. Kelly, R. Esterbauer et al. · 2020 · medRxiv
59. Inside-out assembly of viral antigens for the enhanced vaccination
    Fengqiang Cao, Sha Peng, Yaling An, Kun Xu, Tianyi Zheng, Lianpan Dai, Kenji Ogino, To Ngai, Yufei Xia, Guanghui Ma · 2023 · Signal Transduction and Targeted Therapy
60. Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques
    Laura Solforosi, Lea M. M. Costes, Jeroen T. B. M. Tolboom, Katherine McMahan, Tochi Anioke, David L. Hope, Tetyana Murdza, Michaela Sciacca, Emily Bouffard, Julia Barrett et al. · 2023 · Nature Communications
61. Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant
    V. Müller, L. Polivka, I. Vályi-Nagy, A. Nagy, Z. Szekanecz, K. Bogos, H. Vágó, A. Kamondi, F. Fekete, J. Szlávik et al. · 2022 · Vaccines
62. Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models
    Young-Il Kim, Mark Anthony B. Casel, Young-Ki Choi · 2022 · Journal of Microbiology
63. Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques
    Jing-You Yu, Natalie D. Collins, N. Mercado, K. McMahan, A. Chandrashekar, Jin-Yan Liu, Tochi Anioke, Aiquan Chang, Victoria M. Giffin, David L. Hope et al. · 2021 · bioRxiv
64. Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
    A. Abdoli, R. Aalizadeh, Hossein Aminianfar, Z. Kianmehr, E. Azimi, Nabbi Emamipour, H. Jamshidi, M. Hosseinpour, M. Taqavian, H. Jalili · 2021 · bioRxiv
65. Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters
    N. C. Dalvie, Sergio A. Rodriguez-Aponte, B. Hartwell, Lisa H. Tostanoski, Andrew M. Biedermann, Laura E. Crowell, K. Kaur, Ozan S. Kumru, L. Carter, Jing-You Yu et al. · 2021 · bioRxiv
66. Containing a pandemic: nonpharmaceutical interventions and the ‘second wave’
    Michael Te Vrugt, Jens Bickmann, R. Wittkowski · 2020 · Journal of Physics Communications
67. Toward Understanding Molecular Bases for Biological Diversification of Human Coronaviruses: Present Status and Future Perspectives
    T. Koma, Shun Adachi, Naoya Doi, A. Adachi, Masako Nomaguchi · 2020 · Frontiers in Microbiology
68. A Human-Immune-System (HIS) humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO.IL-2Rγc KO. NOD) for COVID-19
    Teodor-D. Brumeanu, Pooja Vir, A. F. Karim, S. Kar, Dalia Benetiene, Megan Lok, J. Greenhouse, Tammy Putmon-Taylor, Chris Kitajewski, K. Chung et al. · 2020 · bioRxiv
69. Animal Models to Study Emerging Technologies Against SARS-CoV-2
    Jhinuk Basu Mullick, C. Simmons, Janak Gaire · 2020 · Cellular and Molecular Bioengineering
70. Which animals are at risk? Predicting species susceptibility to Covid-19
    Matthew R. Alexander, Clara T. Schoeder, Jacquelyn A. Brown, C. Smart, C. Moth, J. Wikswo, J. Capra, J. Meiler, Wen-Biao Chen, Meena S. Madhur · 2020 · bioRxiv
71. The SARS-CoV-2 antibody-dependent enhancement façade.
    Jeremia M. Coish, Lori A. MacNeil, Adam J. MacNeil · 2024 · Microbes and infection
72. Susceptibility of SARS Coronavirus-2 infection in domestic and wild animals: a systematic review
    Sudhanarayani S. Rao, K. Parthasarathy, Vignesh Sounderrajan, K. Neelagandan, Pradeep Anbazhagan, Vaishnavi Chandramouli · 2022 · 3 Biotech
73. Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
    Dylan M. Johnson, Trevor Brasel, Shane Massey, Tania M. Garron, Michael Grimes, Jeanon N. Smith, Maricela Torres, Shannon M. Wallace, Alejandro G. Villasante Tezanos, David W. C. Beasley et al. · 2022 · Antiviral Research
74. Accelerating model-informed decisions for COVID-19 vaccine candidates using a model-based meta-analysis approach
    Bhargava Kandala, N. Plock, Akshita Chawla, Anna Largajolli, Seth Robey, Kenny J. Watson, R. Thatavarti, Sheri A. Dubey, S. Y. Amy Cheung, R. de Greef et al. · 2022 · EBioMedicine
75. Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19
    Aram Yegiazaryan, Arbi Abnousian, Logan J. Alexander, Ali Badaoui, Brandon Flaig, Nisar Sheren, Armin Aghazarian, Dijla Alsaigh, Arman Amin, Akaash Mundra et al. · 2022 · International Journal of Molecular Sciences
76. Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2
    Hong-Su Park, Y. Matsuoka, Cindy Luongo, Li-Juan Yang, Celia Santos, Xue-Qiao Liu, Laura R. H. Ahlers, Ian N. Moore, Sharmin Afroz, Reed F. Johnson et al. · 2022 · npj Vaccines
77. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity had no antiviral effects but moderately reduced lung inflammation
    K. V. van Rompay, K. Olstad, R. Sammak, Joseph C. Dutra, Jennifer K. Watanabe, J. Usachenko, Ramya Immareddy, Jamin W. Roh, A. Verma, Yashavanth Shaan Lakshmanappa et al. · 2022 · PLoS Pathogens
78. AZD7442 demonstrates prophylactic and therapeutic efficacy in non-human primates and extended half-life in humans
    Yueh-Ming Loo, Patrick M. McTamney, R. Arends, R. Gasser, Michael E. Abram, Anastasia A. Aksyuk, Seme Diallo, Daniel J. Flores, E. J. Kelly, Kui-Shu Ren et al. · 2021 · medRxiv
79. SARS-CoV2 infects pancreatic beta cells in vivo and induces cellular and subcellular disruptions that reflect beta cell dysfunction
    Katelyn Millette, Janielle Cuala, Pei-Yu Wang, C. Marks, Veronica Woo, Maya Hayun, Harsimar Kang, Martin Martin, S. Dhawan, Lily Chao et al. · 2021 · Research Square
80. Subacute SARS-CoV-2 replication can be controlled in the absence of CD8+ T cells in cynomolgus macaques
    T. Nomura, Hiroyuki Yamamoto, M. Nishizawa, T. Hau, S. Harada, Hiroshi Ishii, Sayuri Seki, Midori Nakamura-Hoshi, Midori Okazaki, Sachie Daigen et al. · 2021 · bioRxiv
81. Alemtuzumab in Covid era
    Aniello Iovino, Nunzio Olivieri, Francesco Aruta, E. Giaquinto, L. Ruggiero, E. Spina, S. Tozza, F. Manganelli, R. Iodice · 2021 · Multiple Sclerosis and Related Disorders
82. Durability of the humoral immune response in recovered COVID-19 patients
    Waleed H. Mahallawi, Mohammad Alzahrani, Z. Alahmadey · 2021 · Saudi Journal of Biological Sciences
83. Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera
    KY Oguntuyo, C. Stevens, Chuan-Tien Hung, Satoshi Ikegame, Joshua A. Acklin, S. Kowdle, Jillian C. Carmichael, Hsin-Ping Chiu, Kristopher D. Azarm, Griffin D Haas et al. · 2021 · mBio
84. Understanding the Host Innate Immune Responses against SARS-CoV-2 Infection and COVID-19 Pathogenesis
    Yeon-Woo Kang, Subin Park, Kun-Joo Lee, D. Moon, Young-Min Kim, Seung-Woo Lee · 2021 · Immune Network
85. Further information on possible animal sources for human COVID‐19
    T. Opriessnig, Yao-Wei Huang · 2020 · Xenotransplantation
86. Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19
    Pureum Lee, Doo-Jin Kim · 2020 · Immune Network
87. SARS‐CoV‐2 surveillance for a non‐human primate breeding research facility
    J. Yee, K. V. van Rompay, A. Carpenter, P. Nham, B. Halley, Smita S. Iyer, D. Hartigan-O'Connor, C. Miller, Jeffrey A. Roberts · 2020 · Journal of medical primatology
88. Neutralizing Antibody Levels as a Correlate of Protection Against SARS‐CoV‐2 Infection: A Modeling Analysis
    G. Lingas, D. Planas, H. Péré, F. Porrot, F. Guivel-Benhassine, I. Staropoli, D. Duffy, Nicolas Chapuis, C. Gobeaux, D. Veyer et al. · 2023 · Clinical pharmacology and therapy
89. Effect of adjuvanting RBD-dimer-based subunit COVID-19 vaccines with Sepivac SWE™
    Sen-Yu Xu, Huixin Duan, Yaling An, Xiyue Jin, Min-Run Duan, P. Dubois, Yan Huang, Kun Xu, Heng Du, H. Kleanthous et al. · 2023 · Vaccine
90. An Update on Protective Effectiveness of Immune Responses After Recovery From COVID-19
    Saeede Soleimanian, Soheila Sadat Alyasin, Najmeh Sepahi, Zahra Ghahramani, Zahra Kanannejad, Ramin Yaghobi, Mohammad Hossein Karimi · 2022 · Frontiers in Immunology
91. Epitope mapping of neutralising anti‐SARS‐CoV‐2 monoclonal antibodies: Implications for immunotherapy and vaccine design
    Somayeh Ghotloo, Faezeh Maghsood, Forough Golsaz‐Shirazi, Mohammad Mehdi Amiri, Christiane Moog, Fazel Shokri · 2022 · Reviews in Medical Virology
92. Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time
    Lauren E. Gentles, Leanne Kehoe, Katharine H. D. Crawford, K. Lacombe, Jane A Dickerson, C. Wolf, Joanna Yuan, Susanna L Schuler, J. Watson, Sankan W. Nyanseor et al. · 2022 · medRxiv
93. Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
    Amy C Sherman, Michaël Desjardins, Lindsey Robert Baden · 2021 · Clinics in Laboratory Medicine
94. Blood Analysis of Laboratory Macaca mulatta Used for Neuroscience Research: Investigation of Long-Term and Cumulative Effects of Implants, Fluid Control, and Laboratory Procedures
    D. Wegener, Dan Qi Priscilla Oh, Herbert Lukaß, M. Böer, A. Kreiter · 2021 · eNeuro
95. Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
    Mina Psichοgiou, Andreas Karabinis, Garyphallia Poulakou, Anastasia Antoniadou, Αnastasia Kotanidou, Dimitrios Degiannis, Ioanna D. Pavlopoulou, Antigoni S. Chaidaroglou, Sotirios Roussos, Elpida Mastrogianni et al. · 2021 · Vaccines
96. Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts
    Robert H. Bortz, Catalina Florez, Ethan Laudermilch, Ariel S. Wirchnianski, Gorka Lasso, Ryan J. Malonis, George Ivanov Georgiev, Olivia Vergnolle, Natalia G. Herrera, Nicholas C. Morano et al. · 2021 · mSphere
97. Anti-SARS-CoV-2 IgM improves clinical sensitivity early in disease course
    V. Higgins, Anselmo Fabros, Xiao-Yan Wang, M. Bhandari, D. Daghfal, V. Kulasingam · 2021 · Clinical Biochemistry
98. Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2
    L. Grandjean, A. Saso, A. Torres, T. Lam, J. Hatcher, Rosie Thistlethwayte, M. Harris, Timothy Best, Marina Johnson, H. Wagstaffe et al. · 2020 · medRxiv
99. Case Report: A Recovered SARS CoV-2 Patient Protected From Reinfection
    Waleed H. Mahallawi · 2020 · Frontiers in Medicine
100. Emergence of SARS and COVID-19 and preparedness for the next emerging disease X
     Ben Hu, Hua Guo, Haorui Si, Zhengli Shi · 2024 · Frontiers in Medicine